Philip D. Hall

903 citations

32 papers · 712 indexed · h-index 17

Co-authors: Arthur E. Frankel Robert J. Kreitman Mark C. Willingham Edward P. Tagge Bayard L. Powell L. Douglas Case Tie Fu Liu John B. Bossaer
Topics: Toxin Mechanisms and Immunotoxins (18 papers)Transgenic Plants and Applications (13 papers)Neuroblastoma Research and Treatments (4 papers)
Cited by: Biotechnology Immunology Hematology
Journals: Journal of Clinical Oncology Blood Clinical Cancer Research
Partner nations: United States Canada Australia

In The Last Decade

Philip D. Hall

32 papers receiving 702 citations

Peers

Countries citing papers authored by Philip D. Hall

Since Specialization

Citations

This map shows the geographic impact of Philip D. Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip D. Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip D. Hall more than expected).

Fields of papers citing papers by Philip D. Hall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip D. Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip D. Hall. The network helps show where Philip D. Hall may publish in the future.

Co-authorship network of co-authors of Philip D. Hall

This figure shows the co-authorship network connecting the top 25 collaborators of Philip D. Hall. A scholar is included among the top collaborators of Philip D. Hall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip D. Hall. Philip D. Hall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Report of the 2012-2013 Standing Committee on Advocacy: Advocacy Tools and Resources: A Framework for Increasing Member Engagement 2013 ·American Journal of Pharmaceutical Education ·Marie Smith,(unknown),Julie C. Kissack,Philip D. Hall,George E. MacKinnon,William Lang	3
2	Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE 2010 ·Supportive Care in Cancer ·John B. Bossaer,Philip D. Hall,Elizabeth Garrett‐Mayer	45
3	Single‐Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults 2006 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Anne McDonnell,(unknown),Debra Frei‐Lahr,John Hayslip,Philip D. Hall	60
4	Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: implications for diphtheria fusion protein therapy 2006 ·Cancer Immunology Immunotherapy ·Philip D. Hall,Debajyoti Sinha,Arthur E. Frankel	2
5	Toxicology and Pharmacokinetics of DT₃₈₈IL3, a Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT₃₈₈) Linked to Human Interleukin 3 (IL3), in Cynomolgus Monkeys 2004 ·Leukemia & lymphoma ·(unknown),Tie Fu Liu,J. Mark Cline,Janice D. Wagner,Philip D. Hall,Arthur E. Frankel	27
6	Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey 2004 ·Cancer Immunology Immunotherapy ·(unknown),Tie Fu Liu,J. Mark Cline,Janice D. Wagner,Philip D. Hall,Arthur E. Frankel	24
7	Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials 2003 ·Protein Expression and Purification ·(unknown),(unknown),J Black,(unknown),Philip D. Hall,Mark C. Willingham,(unknown),Donna E. Hogge,Robert J. Kreitman,Arthur E. Frankel	35
8	The Majority of Children and Adolescents With Acute Myeloid Leukemia Have Detectable Anti-DT388-GMCSF IgG Concentrations, but at Concentrations That Should Not Preclude In Vivo Activity 2002 ·Journal of Pediatric Hematology/Oncology ·Philip D. Hall,Bassem I. Razzouk,(unknown),Thomas W. McLean,Arthur E. Frankel	2
9	High-Level Expression and Purification of the Recombinant Diphtheria Fusion Toxin DTGM for PHASE I Clinical Trials 1999 ·Protein Expression and Purification ·Arthur E. Frankel,Jason G. Ramage,(unknown),(unknown),Stephen J. Delatte,Philip D. Hall,Edward P. Tagge,Robert J. Kreitman,Mark C. Willingham	28
10	Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells 1999 ·Leukemia Research ·Caryn N. Kim,Kapil N. Bhalla,Robert J. Kreitman,Mark C. Willingham,Philip D. Hall,Edward P. Tagge,Tao Jia,(unknown)	22
11	Toxicology and Pharmacokinetics of DTGM, a Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT388) Linked to Human Granulocyte-Macrophage Colony-Stimulating Factor, in Cynomolgus Monkeys 1999 ·Toxicology and Applied Pharmacology ·Charlotte E. Hotchkiss,Philip D. Hall,J. Mark Cline,Mark C. Willingham,Robert J. Kreitman,Jean F. Gardin,(unknown),Jason G. Ramage,(unknown),Stephen J. Delatte,Edward P. Tagge,Arthur E. Frankel	20
12	Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. 1998 ·Blood ·Arthur E. Frankel,Michelle M. Lilly,Robert J. Kreitman,Donna E. Hogge,Miloslav Beran,Melvin H. Freedman,Peter D. Emanuel,(unknown),Philip D. Hall,Edward P. Tagge,Marc Berger,Connie J. Eaves	30
13	Toxicology and Pharmacokinetics of DT388-GM-CSF, a Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT388) Linked to Human Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in C57BL/6 Mice 1998 ·Toxicology and Applied Pharmacology ·Philip D. Hall,R. J. Kreitman,Mark C. Willingham,Arthur E. Frankel	11
14	Cell-Specific Modulation of Drug Resistance in Acute Myeloid Leukemic Blasts by Diphtheria Fusion Toxin, DT388-GMCSF 1998 ·Bioconjugate Chemistry ·Arthur E. Frankel,Philip D. Hall,(unknown),Ahmad R. Safa,Edward P. Tagge,Robert J. Kreitman	26
15	Synthesis of Green Fluorescent Protein−Ricin and Monitoring of Its Intracellular Trafficking 1997 ·Bioconjugate Chemistry ·Edward P. Tagge,(unknown),(unknown),Philip D. Hall,(unknown),Mark C. Willingham,Arthur E. Frankel	8
16	The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. 1995 ·PubMed ·Philip D. Hall,(unknown),(unknown),Robert K. Stuart	32
17	Immunomodulation With Intravenous Immunoglobulin 1993 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Philip D. Hall	19
18	Head and Neck Cancer: Detection and Therapeutics 1990 ·American Pharmacy ·Philip D. Hall,Jim M. Koeller	4
19	The Effect of Everyday Exercise on Steady State Digoxin Concentrations 1989 ·The Journal of Clinical Pharmacology ·Philip D. Hall,William R. Garnett,(unknown),(unknown),(unknown)	4
20	Halothane hepatitis in an animal model: time course of hepatic damage. 1987 ·PubMed ·(unknown),G. K. Gourlay,Philip D. Hall,(unknown),Michael J. Cousins	8

About Philip D. Hall

Philip D. Hall is a scholar working on Biotechnology, Immunology and Hematology, having authored 32 papers that have together received 712 indexed citations. Recurring topics across this work include Toxin Mechanisms and Immunotoxins (18 papers), Transgenic Plants and Applications (13 papers) and Neuroblastoma Research and Treatments (4 papers). The work is most often cited by research in Biotechnology (196 citations), Immunology (384 citations) and Hematology (87 citations). Philip D. Hall has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Arthur E. Frankel, Robert J. Kreitman, Mark C. Willingham, Edward P. Tagge, Bayard L. Powell, L. Douglas Case, Arthur E. Frankel, Tie Fu Liu, John B. Bossaer and Elizabeth Garrett‐Mayer. Their work appears in journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact